ArticleThe Prostate2026
Temporal Patterns and Resolution of Toxicities Following Hypofractionated Salvage Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.
Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypofractionated salvage radiotherapy is increasingly used for biochemical recurrence of prostate cancer post-prostatectomy, yet its toxicity profile remains underexplored. This study evaluates the incidence, timing, and resolution of treatment-related toxicities in this setting.
methodsA retrospective cohort study of 403 men receiving hypofractionated salvage radiotherapy (62.5 Gy in 25 fractions) from 2017 to 2024 was conducted. Toxicities, categorized as genitourinary (hematuria, urinary incontinence, frequency, dysuria) or gastrointestinal (rectal bleeding, diarrhea, proctitis, nausea), were graded (1-3) using CTCAE-based criteria. Outcomes included any-time incidence, Kaplan-Meier time-to-first-event estimates (12- and 24-month cumulative incidence), and first-onset timing. Episode-level analyses merged events ≤ 30 days apart, assessing resolution and intervention.
resultsMedian follow-up was 18.2 months. Any-grade genitourinary and gastrointestinal toxicities occurred in 34.2% and 24.6% of patients, respectively (24-month incidence: genitourinary 40.4%; gastrointestinal 28.9%). Grade 2+ toxicities were less frequent (genitourinary 9.7%; gastrointestinal 7.7%), with Grade 3+ rare (genitourinary 1.7%; gastrointestinal 0.7%). In terms of patient-level ever-event incidences, common symptoms included urinary incontinence (20.3%), rectal bleeding (19.9%), and hematuria (13.9%). Urinary toxicities predominantly onset at 6-12 months, whereas rectal bleeding and hematuria emerged later (≥ 12 months). Approximately two-thirds of Grade 2+ episodes resolved (e.g., urinary incontinence, 66.7%; rectal bleeding, 69.2%), with median resolution times of 3.0-8.4 months.
conclusionWith a median follow-up of 18.2 months, hypofractionated salvage radiotherapy demonstrates favorable short-to-intermediate term tolerability, with infrequent severe toxicities. Vigilant monitoring for late-onset rectal bleeding and hematuria is recommended during the 6-24 months after treatment to optimize patient management. Longer follow-up is required to confirm long-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.